ResearchMoz

U.S. Vaccine Market - U.S. Industry Analysis, Size, Share, Growth, And Forecast, 2012 - 2018

Transparency Market Research
Published Date » 2012-09-17
No. Of Pages » 71

This report helps to identify factors, which will be the driving force behind the U.S. vaccine market and sub-markets in the next six years. The report provides extensive analysis of the US vaccine industry, current market trends, industry drivers and challenges for better understanding of the U.S.vaccine market structure. The report has segregated the U.S. vaccine industry in terms of product type. Annual estimates and forecasts are provided for the period 2012 through 2018 in terms of in USD million.

The report helps in providing a comprehensive overview for
  • Market forces that are driving and restraining the growth of the industry
  • Opportunities for the application segments 
  • Up-to-date analysis of the latest trends in the industry 
  • Acumen into the size and shape of the market growth
  • Detailed outlook of the market and its future

Reasons for buying this report
  • Forward-looking perspective on a category, market or issue affecting the industry growth
  • Six year forecast assess how the market is predicted to grow and segmental behavior
  • Understand the competitive environment, the leading players and segments in the market
  • Clear understanding about the key product segments and identification of most robust product segment will help in ensuring strong returns
  • Pin-point analysis of changing dynamics of competition keeps you ahead of the competitors
  • Make more informed business decisions from insightful and in-depth analysis of the technical and commercial strength of U.S. vaccine Market andits performance 
  • Observe the chronological sales performance of a U.S. vaccine Marketin major regional markets 
  • Obtain sales forecast for currently marketed U.S. vaccine Market application for 2012 – 2018 for the U.S. market

Major Segments Analyzed
  • Human vaccine
  • Pediatric vaccines
  • Adult &adolescent vaccine
  • Other human vaccine
  • Animal vaccine
  • Livestock vaccine
  • Bovine vaccine
  • Porcine vaccine
  • Ovine vaccine
  • Companion animal vaccine
  • Feline vaccine
  • Canine vaccine
  • Equine vaccine
  • Other animal vaccine

Methodology

For the research report, we conducted in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents the bulk of our research efforts, supplemented by extensive secondary research. We reviewed the key players’ product literature, annual reports, press releases and relevant documents for competitive analysis and market understanding. Secondary research also includes a search of recent trade journals, technical writing, internet sources, and statistical data from government websites, trade associations and agencies. This approach has proven to be the most reliable, effective and successful approach for obtaining precise market data, capturing industry participants’ insights, and recognizing business opportunities.
TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 METHODOLOGY

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 U.S. VACCINE MARKET, 2012 - 2018
3.1 MARKET OVERVIEW
3.2 VACCINE MARKET CHARACTERISTICS
3.3 LAWS AND REGULATIONS
3.3.1 VACCINE APPROVAL PROCESS
3.4 U.S. VACCINE MARKET ESTIMATE AND FORECAST, 2012 - 2018
3.4.1 MARKET SHARE BY VACCINE TYPE
3.5 LIST OF COMPANIES SUPPLYING VACCINES IN THE U.S.
3.6 VACCINE PRICING
3.6.1 PRICES FOR VACCINES CONTAINING THIMEROSAL AS A PRESERVATIVE
3.6.2 PRICES OF VACCINES FREE OF PRESERVATIVES:
3.7 MARKET DYNAMICS
3.7.1 DRIVERS
3.7.1.1 Rise in incidences of viral infection driving the growth of vaccine market in the U.S.
3.7.1.2 Biotechnology research enabling synthesis of new vaccines to target complex human diseases driving the vaccine market
3.7.1.3 Government recommendation for adult and adolescent immunization will boost the growth of Vaccine market in U.S.
3.7.1.4 Rise in infectious diseases in animals driving the market
3.7.2 RESTRAINTS
3.7.2.1 Cost of refrigeration
3.7.2.2 Short functional shelf life of certain vaccines will have negative impact on the market growth
3.7.3 OPPORTUNITIES
3.7.3.1 Huge product pipeline of the multinational firms will act as an opportunity for future growth
3.8 IMPACT ANALYSIS OF DRIVERS
3.9 IMPACT ANALYSIS OF RESTRAINTS
3.10 PORTER’S FIVE FORCE ANALYSIS
3.10.1 BARGAINING POWER OF SUPPLIER
3.10.2 BARGAINING POWER OF BUYER
3.10.3 RIVALRY AMONG EXISTING COMPETITORS
3.10.4 THREAT OF NEW ENTRANTS
3.10.5 THREAT OF SUBSTITUTE

CHAPTER 4 U.S. VACCINE MARKET BY PRODUCT TYPE
4.1 HUMAN VACCINE
4.1.1 MARKET ANALYSIS, SIZE AND FORECAST
4.1.2 MARKET ATTRACTIVENESS ANALYSIS FOR HUMAN VACCINE MARKET
4.1.3 PEDIATRIC VACCINES
4.1.3.1 Market Analysis, Size and Forecast
4.1.3.2 Pediatric vaccine price list
4.1.3.3 Pediatric Influenza Vaccine price list
4.1.3.4 HaemophilusInfluenzae Type B
4.1.3.4.1 Hib Pricing
4.1.3.5 Hepatitis A
4.1.3.5.1 HAV Pricing
4.1.3.6 Hepatitis B
4.1.3.6.1 Hepatitis B Pricing
4.1.4 ADULT & ADOLESCENT VACCINES
4.1.4.1 Market Analysis, Size and Forecast
4.1.4.2 Adult vaccine price list
4.1.4.3 Adult Influenza Vaccine price list
4.1.5 OTHER HUMAN VACCINES
4.1.5.1 Market Analysis, Size and Forecast
4.2 ANIMAL VACCINE
4.2.1 MARKET ANALYSIS, SIZE AND FORECAST
4.2.2 MARKET ATTRACTIVENESS ANALYSIS FOR ANIMAL VACCINE
4.2.3 LIVESTOCK VACCINES
4.2.3.1 Market Analysis, Size and Forecast
4.2.3.2 Bovine Vaccines
4.2.3.2.1 Market Analysis, Size and Forecast
4.2.3.3 Porcine Vaccines
4.2.3.3.1 Market Analysis, Size and Forecast
4.2.3.4 Ovine Vaccines
4.2.3.4.1 Market Analysis, Size and Forecast
4.2.4 COMPANION ANIMAL VACCINES
4.2.4.1 Market Analysis, Size and Forecast
4.2.4.2 Feline Vaccines
4.2.4.2.1 Market Analysis, Size and Forecast
4.2.4.3 Canine Vaccines
4.2.4.3.1 Market Analysis, Size and Forecast
4.2.4.4 Equine Vaccines
4.2.4.4.1 Market Analysis, Size and Forecast
4.2.5 OTHER ANIMAL VACCINES
4.2.5.1 Market Analysis, Size and Forecast

CHAPTER 5 COMPETITIVE LANDSCAPE
5.1 MARKET SHARE ANALYSIS
5.2 COMPETITIVE ANALYSIS FOR KEY MARKET PLAYERS

CHAPTER 6 COMPANY PROFILE
6.1 SANOFI-AVENTIS
6.1.1 COMPANY OVERVIEW
6.1.2 FINANCIAL OVERVIEW
6.1.3 SWOT ANALYSIS
6.1.1 RECENT DEVELOPMENT
6.2 GLAXOSMITHKLINE
6.2.1 COMPANY OVERVIEW
6.2.2 FINANCIAL OVERVIEW:
6.2.3 SEGMENT OVERVIEW
6.2.4 SWOT ANALYSIS
6.2.5 RECENT DEVELOPMENTS
6.3 MERCK & COMPANY INCORPORATED
6.3.1 COMPANY OVERVIEW
6.3.2 FINANCIAL OVERVIEW:
6.3.1 RECENT DEVELOPMENT
6.4 PFIZER INCORPORATED
6.4.1 COMPANY OVERVIEW
6.4.2 FINANCIAL OVERVIEW
6.4.3 RECENT DEVELOPMENT
6.5 ASTRAZENECA PLC
6.5.1 COMPANY OVERVIEW
6.5.2 FINANCIAL OVERVIEW:
6.5.3 RECENT DEVELOPMENT
6.6 NOVARTIS AG
6.6.1 COMPANY OVERVIEW
6.6.2 FINANCIAL OVERVIEW:
6.6.3 SWOT ANALYSIS
6.6.1 RECENT DEVELOPMENT
6.7 BOEHRINGER
6.7.1 COMPANY OVERVIEW
6.7.2 NET SALES BY BUSINESS
6.7.3 SWOT ANALYSIS
6.7.4 RECENT DEVELOPMENT



List of Tables


TABLE 1 ACTS AND REGULATIONS PERTINENT TO VACCINE DEVELOPMENT 
TABLE 2 SELECT FDA AND ICH GUIDANCE DOCUMENTS RELEVANT TO VACCINE DEVELOPMENT 
TABLE 3 LOT-RELEASE TESTING GUIDLINES 
TABLE 1 U.S. VACCINE MARKET REVENUE, BY PRODUCT TYPE, 2012 - 2018, (USD MILLION) 
TABLE 2 GSK PRODUCT PIPELINE 
TABLE 3 U.S. HUMAN VACCINE MARKET REVENUE, BY PRODUCT TYPE 2012 - 2018 (USD MILLION) 
TABLE 4 U.S. ANIMAL VACCINE MARKET REVENUE, BY PRODUCT TYPE 2012 - 2018 (USD MILLION) 
TABLE 5 U.S. LIVESTOCK VACCINES MARKET REVENUE, BY PRODUCT TYPE 2012 - 2018 (USD MILLION) 
TABLE 6 U.S. COMPANION ANIMAL VACCINES MARKET REVENUE, BY PRODUCT TYPE 2012- 2018 (USD MILLION) 

List of Figures


FIG. 1 U.S. VACCINE MARKET REVENUE, BY PRODUCT TYPE, 2012 - 2018, (USD MILLION) 
FIG. 2 FDA REGULATORY REVIEW PROCESS 
FIG. 3 VACCINE APPROVAL PROCESS 
FIG. 4 U.S. VACCINE MARKET REVENUE, 2010 - 2018 (USD MILLION) 
FIG. 5 U.S. VACCINE MARKET SHARE, BY VACCINE TYPE 2012 ESTIMATE (%) 
FIG. 6 IMPACT ANALYSIS OF DRIVERS 
FIG. 7 PORTER’S FIVE FORCE ANALYSIS FOR U.S. VACCINE MARKET 
FIG. 8 U.S. HUMAN VACCINE MARKET REVENUE2010 - 2018(USD MILLION) 
FIG. 9 MARKET ATTRACTIVENESS ANALYSIS FOR U.S. HUMAN VACCINE MARKET 
FIG. 10 PEDIATRIC VACCINES MARKET REVENUE 2010 – 2018 (USD MILLION) 
FIG. 11 ADULT & ADOLESCENT VACCINESMARKETREVENUE 2010 - 2018(USD MILLION) 
FIG. 12 OTHER HUMAN VACCINESMARKETREVENUE2010 - 2018(USD MILLION) 
FIG. 13 U.S. ANIMAL VACCINEMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 14 MARKET ATTRACTIVENESS FOR U.S. ANIMAL VACCINE MARKET2012 
FIG. 15 LIVESTOCK VACCINESMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 16 BOVINE VACCINES MARKETREVENUE 2010 - 2018 (USD MILLION) 
FIG. 17 PORCINE VACCINESMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 18 OVINE VACCINES MARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 19 COMPANION ANIMAL VACCINESMARKETREVENUE2010 - 2018 (USD MILLION), 
FIG. 20 FELINE VACCINESMARKETREVENUE2010-2018 (USD MILLION) 
FIG. 21 CANINE VACCINESMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 22 EQUINE VACCINESMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 23 OTHER ANIMAL VACCINESMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 24 MARKET SHARE OF MAJOR HUMAN VACCINE PRODUCERS IN THE U.S., 2011 (%) 
FIG. 25 MARKET SHARE OF MAJOR ANIMAL VACCINE PRODUCERS IN THE U.S., 2011 (%) 
FIG. 26 GLOBAL VACCINE PLAYERS SALES GROWTH 2012-2018 
FIG. 27 SANOFI-AVENTIS, PERFORMANCE CHART (2009-2011) 
FIG. 28 SANOFI-AVENTIS, SWOT ANALYSIS 
FIG. 29 GLAXOSMITHKLINE PLC AG, PERFORMANCE CHART (2006-2010) 
FIG. 30 GLAXOSMITHKLINE PLC AG, MARKET SHARE BY SEGMENT IN 2011 
FIG. 31 GLAXOSMITHKLINE PLC AG, SWOT ANALYSIS 
FIG. 32 MERCK & CO. , PERFORMANCE CHART (2007-2011) 
FIG. 33 MERCK, SWOT ANALYSIS 
FIG. 34 MERCK & CO. , PERFORMANCE CHART (2007-2011) 
FIG. 35 ASTRAZENECA PLC, MARKET SHARE BY SEGMENT IN 2011 
FIG. 36 ASTRAZENECA PLC, SWOT ANALYSIS 
FIG. 37 NOVARTIS AG, PERFORMANCE CHART (2007-2011) 
FIG. 38 NOVARTIS AG, SWOT ANALYSIS 
FIG. 39 BOEHRINGER, SWOT ANALYSIS 

Upcoming Reports:

HPV Therapeutic Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Human Papillomaviruses (HPV) are members of papillomaviridae family a group of more than 150 related viruses. These are specifically known as papillomaviruses because of some of its types give rise to a wart or papilloma which are benign growths. Some of them are also associated with certain cancers and known as carcinogenic HPVs. More than 40 types of HPV viruses are easily transferred from one person to another by sexual contact anal and oral. Ithas estimated worldwide prevalence of HPV induced cancer in approximately 12-13%. Cervical cancer is the second largest cause of cancer deaths...
Neurostimulation Market - Advanced Technologies, Global Market and Industry Analysis, Size, Trends and Forecast, 2012 - 2018
By - Transparency Market Research
Driven by rising health awareness and continuous disruptive innovations made in the field of medical and biological technologies, the global market for neurostimulation is expected to reach a market size valued at USD 7.3 billion in year 2018. The market is expected to grow at a healthy CAGR of 8.2% from 2012 – 2018. It was estimated at USD 4.2 billion in 2011. Medical devices manufacturing companies and their technological affiliates or subsidiaries are continuously working on developing novel devices and technologies which can enhance the efficacy of existing...
Phosgene Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018
By - Transparency Market Research
Phosgene is a colorless chemical compound produced by reacting chlorine and carbon monoxide. It has a suffocating odor and a small amount of phosgene is released in nature from volcanoes. It is mainly produced artificially and is extremely toxic and due to this, it was even used as a chemical weapon during wars. Phosgene is used for deriving a number of chemical compounds used in various industrial sectors. Diethylcarbamoyl chloride a derivative of phosgene and is used to hydrolyze water insoluble compounds and is extensively used in the pharmaceutical industry.  Tetra...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Top End Stereo Systems Maker Harman Targets Chinese Auto Market
Apr 22, 2014  
Harman, the U.S.-based audio company that is best known as the provider of automobile stereos for top-end car models such as Mercedes-Benz, BMW and Ferrari, has said that it has signed agreements with two leading Chinese automakers—Chang’An and Geely. The company, that is associated with premium infotainment systems for leading auto makers, said that these new contracts...
Scientists Identify Cure for Dengue
Apr 18, 2014  
In a breakthrough discovery that can change the way dengue is treated, scientists have identified a drug target for the deadly dengue viruses. This discovery may help pave the way for discovery of vaccines that can cure this condition that affects nearly 390 million people throughout the world each year.  Scientists have used a new technique for this discovery to show that a region...
India is Facing a Cancer Crisis
Apr 15, 2014  
India is currently facing a cancer crisis – reports a recent research carried out at the King’s college London, in collaboration with the Tata Memorial Cancer Centre, Mumbai.  The reasons estimated for this crisis comprise of increasing rates of smoking, unequal access to proper treatment and belated diagnosis.  Every year, India witnesses around one...
Microparticle Tags to Check Counterfeit Goods Invented
Apr 14, 2014  
Researchers from the Massachusetts Institute of Technology have invented a new set of microparticles that can easily be read by smartphones and establish the authenticity of currency, electronic items and luxury goods.  This strategy is among those countless measures taken by big brands and companies to label their legitimate products in order to stop illegal copies of the...
USFDA Approves Lupins Generic Diabetic Drug
Apr 10, 2014  
The United States Food and Drugs Administration (USFDA) has finally approved Lupin Pharmaceuticals Inc (LPI), the American subsidiary of Indian drug manufacturers Lupin Ltd, to sell Pioglitazone Tablets in the U.S market. The approval has been granted first for fiscal 2015.  Pioglitazone is a generic medicine used for managing diabetes and is a version of Actos tablets...